Safety and Immunogenicity Study of GSK Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK23211381A) Manufactured With a New Process in Adults and Children

Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK23211381A) Manufactured With a New Process in Adults and Children

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs GSK 2321138A (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline Biologicals
  • Most Recent Events

    • 17 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 10 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 09 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Apr 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top